Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor (GLP-1R) agonists are U.S. Food and Drug Administration–approved weight loss drugs. Despite their widespread use, the sites of action through which GLP-1R agonists (GLP1RAs) affect appetite and body weight are still not fully understood. We determined whether GLP-1Rs in either GABAergic or glutamatergic neurons are necessary for the short- and long-term effects of the GLP1RA liraglutide on food intake, visceral illness, body weight, and neural network activation. We found that mice lacking GLP-1Rs in vGAT-expressing GABAergic neurons responded identically to controls in all parameters measured, whereas deletion of GLP-1Rs in vGlut2-expressing glutamatergic neurons eliminated liraglutide-induced weight loss and visceral illness and severely attenuated its effects on feeding. Concomitantly, deletion of GLP-1Rs from glutamatergic neurons completely abolished the neural network activation observed after liraglutide administration. We conclude that liraglutide activates a dispersed but discrete neural network to mediate its physiological effects and that these effects require GLP-1R expression on glutamatergic but not GABAergic neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs apparently only activate a subset of brainstem GLP-1R neurons, particularly in the NTS (65, 117).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 13,437
Primer3—new capabilities and interfaces
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B. C., Remm, M., & Rozen, S. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,461
The mouse brain in stereotaxic coordinates
Konsman, J.-P. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00088-x · Cited by 4,045 · cited 5×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialThe Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“GLP-1R is expressed in the pancreas, heart, kidney, gastrointestinal tract, and brain (1).”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“In rats, intracerebroventricular injection of a specific GLP-1R antagonist, exendin(9-39) has been shown to increase food intake in the short and long term, suggesting that neuronal GLP-1Rs contribute to normal feeding behavior (43,44).”
BackgroundBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“As such, long-acting synthetic GLP-1R agonists (GLP1RAs) are useful therapeutic agents to treat type 2 diabetes (2).”
BackgroundLeptin Action on GABAergic Neurons Prevents Obesity and Reduces Inhibitory Tone to POMC Neurons
Vong, L., Ye, C., Yang, Z., Choi, B., Chua, S., & Lowell, B. B. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.028 · Cited by 1,235
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 7×
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluential
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“The anorexigenic and weight-lowering effects of liraglutide are blunted upon genetic ablation of GLP-1R in glutamatergic neurons, yet fully preserved when GLP-1R is deleted in GABAergic neurons [718].”
BackgroundSelf-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
HypoMap—a unified single-cell gene expression atlas of the murine hypothalamus
Steuernagel, L., Lam, B. Y. H., Klemm, P., Dowsett, G. K. C., Bauder, C. A., Tadross, J. A., Hitschfeld, T. S., del Rio Martin, A., Chen, W., de Solis, A. J., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00657-y · Cited by 267
Central and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265
Area postrema cell types that mediate nausea-associated behaviors
Zhang, C., Kaye, J. A., Cai, Z., Wang, Y., Prescott, S. L., & Liberles, S. D. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.010 · Cited by 263
“…that mediate satiety and nausea to exendin-4, consistent with a model that feeding inhibition involves GLP1R neurons in several brain regions (Adams et al., 2018; Burmeister et al., 2017; Fortin et al., 2020; Ghosal et al., 2017; Secher et al., 2014) while aversion involves a more focal…”
BackgroundSelf-citationPharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
A genetic map of the mouse dorsal vagal complex and its role in obesity
Ludwig, M. Q., Cheng, W., Gordian, D., Lee, J., Paulsen, S. J., Hansen, S. N., Egerod, K. L., Barkholt, P., Rhodes, C. J., Secher, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00363-1 · Cited by 186
Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“…actions, though whether this includes action on GLP-1 receptors inside the BBB or is limited to direct activation of GLP-1 receptors in the circumventricular organs outside the BBB, is less clear (Adams et al., 2018; Gabery et al., 2020; Gu et al., 2013; Salinas et al., 2018; Secher et al., 2014).”
BackgroundInfluentialLi, C., Navarrete, J., Liang-Guallpa, J., Lu, C., Funderburk, S. C., Chang, R. B., Liberles, S. D., Olson, D. P., & Krashes, M. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.016 · Cited by 145
“Supporting this finding is recent work showing that liraglutide failed to elicit Fos activity in the PVH, while the large majority of induction occurs in Glp1r-bearing hindbrain neurons (Adams et al., 2018).”
Self-citationHe, Z., Gao, Y., Lieu, L., Afrin, S., Cao, J., Michael, N. J., Dong, Y., Sun, J., Guo, H., & Williams, K. W. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.008 · Cited by 128
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
“In addition, the AP is one of the most c-Fos–responsive areas of the brain following peripheral liraglutide (21, 36), and it is possible that part of the observed neural activity within the NTS (34, 36) is secondary to AP GLP-1R activation.”
BackgroundInfluentialMetabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 146
“Liraglutide-induced anorexia is also related with glutamatergic POMC neuron, leading to weight loss [169].”
BackgroundKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“Recent work also suggests glutamatergic neurons, not GABAergic neurons, may be the primary cell type responsible for the liraglutide-induced decrease in food intake and body weight (Tables 2 and 3) (Adams et al., 2018).”
BackgroundGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Further detail was provided by Adams et al. 114 , who investigated the importance of GLP-1Rs in mice using targeted deletions of the receptor, with the aim of discovering whether GABAergic or glutamatergic neurons of the CNS were essential for the short-term and long-term effects of liraglutide on food intake, viscera…”
Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124
Hindbrain circuits in the control of eating behaviour and energy balance
Cheng, W., Gordian, D., Ludwig, M. Q., Pers, T. H., Seeley, R. J., & Myers, M. G. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00606-9 · Cited by 134
Self-citationCheng, W., Gonzalez, I., Pan, W., Tsang, A. H., Adams, J., Ndoka, E., Gordian, D., Khoury, B., Roelofs, K., Evers, S. S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.012 · Cited by 123
Self-citationVarin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
“A combination of pharmacological studies, optogenetics, chemogenetics, cell ablation, and cell-specific knockdown of the GLP-1R within the CNS implicates multiple neural GLP-1R circuits in the control of food intake, reward, and body weight (Adams et al., 2018; Burmeister et al., 2017; Hayes et al., 2011; Holt et al.,…”
BackgroundInfluentialSelf-citationA Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
GFRAL-expressing neurons suppress food intake via aversive pathways
Sabatini, P. V., Frikke-Schmidt, H., Arthurs, J., Gordian, D., Patel, A., Rupp, A. C., Adams, J. M., Wang, J., Beck Jørgensen, S., Olson, D. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021357118 · Cited by 100
Self-citationCheng, W., Ndoka, E., Hutch, C., Roelofs, K., MacKinnon, A., Khoury, B., Magrisso, J., Kim, K. S., Rhodes, C. J., Olson, D. P., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134359 · Cited by 97
Self-citationSilver, H. J., Olson, D., Mayfield, D., Wright, P., Nian, H., Mashayekhi, M., Koethe, J. R., Niswender, K. D., Luther, J. M., & Brown, N. J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15113 · Cited by 94
“It is thought that these effects occur by activating GLP-1 receptors expressed on glutamatergic neurons in the hypothalamus.(49) In the present study of obesity and prediabetes, similar increased sensations of satiation and satiety were observed with liraglutide treatment as participants rated their feeling of fullnes…”
BackgroundSelf-citationDong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
Self-citationLu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91
“This increase correlated with a rebound effect on BW and food intake, a phenomenon observed earlier with long-acting GLP-1Ra.(46) Hepatic and adipose lipogenesis are inhibited with GLP-1.”
BackgroundQue, Q., Guo, X., Zhan, L., Chen, S., Zhang, Z., Ni, X., Ye, B., & Wan, S. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0218-y · Cited by 90
A novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Graham, D. L., Durai, H. H., Trammell, T. S., Noble, B. L., Mortlock, D. P., Galli, A., & Stanwood, G. D. (2020) · Journal of Comparative Neurology · doi:10.1002/cne.24905 · Cited by 88
“However, others note that GLP-1R co-expressed in glutamatergic—not GABAergic— neurons within the hypothalamus and other extrahypothalamic regions are responsible for the physiological functions of GLP-1R agonists (Adams et al., 2018).”
BackgroundEnteroendocrine cell regulation of the gut-brain axis
Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 102
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
“On the other hand, in vivo, liraglutide induces weight loss and reduction in food intake [214], and it has been proposed that the glutamatergic hypothalamic neurons were required for the liraglutide-induced effect [215].”
BackgroundCosta, A., Ai, M., Nunn, N., Culotta, I., Hunter, J., Boudjadja, M. B., Valencia-Torres, L., Aviello, G., Hodson, D. J., Snider, B. M., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101407 · Cited by 79
Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 71
“Indeed, even within the NTS, recent reports have clearly indicated that glutamatergic (Adams et al., 2018) and GABAergic (Fortin et al., 2020) neurons expressing GLP-1Rs are both needed to observe full intake suppression following GLP-1 ligand delivery.”
BackgroundWhole-brain activation signatures of weight-lowering drugs
Hansen, H. H., Perens, J., Roostalu, U., Skytte, J. L., Salinas, C. G., Barkholt, P., Thorbek, D. D., Rigbolt, K. T. G., Vrang, N., Jelsing, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101171 · Cited by 66
Pribiag, H., Shin, S., Wang, E. H.-J., Sun, F., Datta, P., Okamoto, A., Guss, H., Jain, A., Wang, X.-Y., Freitas, B. D., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.05.002 · Cited by 67
“Due to the predominantly GABAergic VP DRD3+ neuronal input to the VTA, we focused our analysis on cells with inhibitory ChR2-mediated responses.”
InfluentialSuppression of food intake by Glp1r/Lepr-coexpressing neurons prevents obesity in mouse models
Rupp, A. C., Tomlinson, A. J., Affinati, A. H., Yacawych, W. T., Duensing, A. M., True, C., Lindsley, S. R., Kirigiti, M. A., MacKenzie, A., Polex-Wolf, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci157515 · Cited by 55
“…EGFP-L10a ) mice (26), Lepr Cre mice (The Jackson Laboratory, 032457) (26), ROSA26 CAG-LSL-FSF-eGFP-L10a (RCFL EGFP-L10a ) (31), ROSA-26 CAG-Sun1/sfGFP (The Jackson Laboratory, 030952) (17), Slc32a1Cre (The Jackson Laboratory, 028862) (14), and Glp1r LSL mice (38) have been described previously.”
InfluentialSelf-citationMolecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety
Webster, A. N., Becker, J. J., Li, C., Schwalbe, D. C., Kerspern, D., Karolczak, E. O., Bundon, C., Onoharigho, R. A., Crook, M., Jalil, M., et al. (2023) · doi:10.1101/2023.10.31.564990 · Cited by 56
Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety
Webster, A. N., Becker, J. J., Li, C., Schwalbe, D. C., Kerspern, D., Karolczak, E. O., Bundon, C. B., Onoharigho, R. A., Crook, M., Jalil, M., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01168-8 · Cited by 55
“Along with other Glp1r + neural cell populations 8,61,87,88 , we propose that TRH Arc neurons are part of a distributed network of neural cells through which GLP-1 signalling suppresses feeding.”
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence
Herman, R. J., & Schmidt, H. D. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114565 · Cited by 62
Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
Liberini, C. G., Koch-Laskowski, K., Shaulson, E., McGrath, L. E., Lipsky, R. K., Lhamo, R., Ghidewon, M., Ling, T., Stein, L. M., & Hayes, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44591-8 · Cited by 50
Chen, Z., Deng, X., Shi, C., Jing, H., Tian, Y., Zhong, J., Chen, G., Xu, Y., Luo, Y., & Zhu, Y. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178239 · Cited by 48
“The anorectic and nausea-inducing responses to these agents critically depend on the activation of GLP-1Rs within the central nervous system (CNS) (9–11, 23, 25, 26, 40, 57); whether these effects arise from different brain regions remains an open question.”
Le, T. D. V., Fathi, P. A., Watters, A. B., Ellis, B. J., Besing, G.-L. K., Bozadjieva-Kramer, N., Perez, M. B., Sullivan, A. I., Rose, J. P., Baggio, L. L., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101718 · Cited by 50
“Mice lacking Glp1r in glutamatergic (Vglut2Glp1r / ) and Wnt1-expressing (Wnt1Glp1r / ) neurons were generated by crossing vGlut2-Cre or Wnt1-Cre mice, respectively, with floxed-Glp1r mice as described previously [13,14].”
BackgroundMethodSelf-citationNutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications
March, C. A., BECKER, D. J., & Libman, I. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622901 · Cited by 53
Obesity pharmacotherapy: incretin action in the central nervous system
Boer, G. A., Hay, D. L., & Tups, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.11.001 · Cited by 52
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Gao, G., Gao, D., Zhao, X., Xu, S., Zhang, K., Wu, R., Yin, C., Li, J., Xie, Y., Hu, S., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.602583 · Cited by 61
Park, J. S., Kim, K. S., & Choi, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0106 · Cited by 59
“GLP-1R is expressed in the AP and nucleus of the solitary tract (NTS) located in the hindbrain, and c-Fos expression after GLP-1RA injection was apparent in hindbrain GLP-1R cells, with further studies demonstrating these cells’ role in mediating GLP-1RA actions [59,96,102,103].”
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“The NTS population may only be partially accessible to peripherally administered GLP-1RAs (16, 64), and GLP-1RAs apparently only activate a subset of brainstem GLP-1R neurons, particularly in the NTS (65, 117).”
InfluentialBuller, S., & Blouet, C. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00250.2023 · Cited by 40
Ratner, C., He, Z., Grunddal, K. V., Skov, L. J., Hartmann, B., Zhang, F., Feuchtinger, A., Bjerregaard, A., Christoffersen, C., Tschöp, M. H., et al. (2019) · Diabetes · doi:10.2337/db18-1009 · Cited by 40
“However, others have challenged the necessity of Pomc neurons for liraglutide to reduce food intake (30,40,41), and a model where several sites and neuronal populations in the brain contribute to liraglutide-induced anorexia is emerging (42).”
BackgroundSingle-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
Ludwig, M. Q., Todorov, P. V., Egerod, K. L., Olson, D. P., & Pers, T. H. (2021) · Diabetes · doi:10.2337/dbi21-0003 · Cited by 38
“Moreover, GLP1R in glutamatergic and not GABAergic neurons are required for weight loss induced by peripherally administered GLP1RA in mice (14).”
BackgroundSelf-citationHarnessing cyclotides to design and develop novel peptide GPCR ligands
Muratspahić, E., Koehbach, J., Gruber, C. W., & Craik, D. J. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00062k · Cited by 36
Glucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function
Davis, E., & Sandoval, D. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190025 · Cited by 60
Self-citationMohajeri, M., Horriatkhah, E., & Mohajery, R. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00881-0 · Cited by 37
Allingbjerg, M.-L., Hansen, S. N., Secher, A., & Thomsen, M. (2022) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000620 · Cited by 37
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Wagner, S., Brierley, D. I., Leeson-Payne, A., Jiang, W., Chianese, R., Lam, B. Y. H., Dowsett, G. K. C., Cristiano, C., Lyons, D., Reimann, F., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101665 · Cited by 32
“However, GLP-1R agonists show limited brain penetrance, at least acutely [2,10,11], and liraglutide-induced cFOS in neurons beyond the cir-cumventricular organs is found primarily in cells not expressing GLP-1Rs [12].”
Modulating effects of RAMPs on signaling profiles of the glucagon receptor family
Shao, L., Chen, Y., Zhang, S., Zhang, Z., Cao, Y., Yang, D., & Wang, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.028 · Cited by 34
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice
Décarie-Spain, L., Fisette, A., Zhu, Z., Yang, B., DiMarchi, R. D., Tschöp, M. H., Finan, B., Fulton, S., & Clemmensen, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.035 · Cited by 27
“…if the benefits of GLP-1/Dexa on food reward are mediated directly via GLP-1R positive neurons in the mesolimbic reward system or, for example, if GLP-1/Dexa acts via glutamatergic neurons in the circumventricular organs as a gateway to access behavioral neurocircuits (Adams et al., 2018).”
Wean, J., Kowalsky, A. H., Laker, R., Will, S., Drucker, D. J., Rhodes, C. J., & Seeley, R. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102074 · Cited by 28
“Unlike what was found here for GIPR, GLP-1R agonists require GLP-1 signaling on glutamatergic but not GABAergic neurons [55], though this fi nding is not universally agreed upon [56].”
Self-citationZeng, N., Cutts, E. J., Lopez, C. B., Kaur, S., Duran, M., VIRKUS, S., & Hardaway, J. A. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.724030 · Cited by 27
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
Shi, Y., Yin, M., Song, Y., Wang, T., Guo, S., Zhang, X., Sun, K., & Li, Y. (2020) · Journal of Biomaterials Applications · doi:10.1177/0885328220947889 · Cited by 25
“Liraglutide, one of these analogs, was approved by the US Food and Drug Administration in 2010 and is mainly used for the treatment of type 2 diabetes.(7) Compared with other commercially available GLP-1 analogs, the half-life of liraglutide has been extended significantly, reducing the drug administration frequency,…”
MethodThe interplay between leptin, glucocorticoids, and GLP1 regulates food intake and feeding behaviour
Perez‐Leighton, C. E., Kerr, B., Scherer, P. E., Baudrand, R. F., & Cortés, V. (2023) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.13039 · Cited by 27
“…by systemic administration of GLP1R agonists such as liraglutide in animals are largely dependent on their action in the central nervous system (Adams et al ., 2018; Beiroa et al ., 2014; Sisley et al ., 2014; Fortin et al ., 2020), which requires GLP1R-mediated transport across the blood –…”
BackgroundGLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
“GLP-1R in glutamatergic but not GABAergic neurons was required for this effect (122).”
Neuroendocrine Peptides of the Gut and Their Role in the Regulation of Food Intake
Schalla, M. A., Taché, Y., & Stengel, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200007 · Cited by 30
Physiology of Energy Intake in the Weight‐Reduced State
Berthoud, H., Seeley, R. J., & Roberts, S. B. (2021) · Obesity · doi:10.1002/oby.23080 · Cited by 25
Self-citationRISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome
Meyer, R. K., & Duca, F. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0019 · Cited by 28
Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist
Grunddal, K. V., Diep, T. A., Petersen, N., Tough, I. R., Skov, L. J., Liu, L.-Z., Buijink, J. A., Mende, F., Jin, C., Jepsen, S. L., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101207 · Cited by 19
Differentiating visceral sensory ganglion organoids from induced pluripotent stem cells
Ahn, K., Park, H.-S., Choi, S., Lee, H.-J., Choi, H., Hong, S. B., Han, J., Han, J. W., Ahn, J.-C., Song, J., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02455-8 · Cited by 21
“3a,c and Supplementary Videos 1 and 2) 23,24 .”
Neural pathways of nausea and roles in energy balance
Zhang, C. (2025) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2024.102963 · Cited by 20
“While GLP1R agonists have various peripheral effects, such as reducing blood glucose through the pancreas, the suppression of feeding primarily originates from targets in the central nervous system [62,63].”
Rodríguez, R., Hergarden, A. C., Krishnan, S., Morales, M., Lam, D., Tracy, T., Tang, T., Patton, A., Lee, C. R., Pant, A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102156 · Cited by 34
Liraglutide Accelerates Ischemia‐Induced Angiogenesis in a Murine Diabetic Model
Zhu, Y., Li, Y., Ma, Y., Zhang, X., Du, X., Gao, J., Ding, N., Wang, L., Chen, N., Luo, M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.026586 · Cited by 21
“Consistent with the results reported in the literature, 25,26 liraglutide suppressed the body weight gain, lowered plasma glucose levels, and enhanced insulin secretion.”
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“Consistent with such assumption is the observation that GLP-1R neurons implicated in food intake control are exclusively glutamatergic [109], and while long-acting GIPR agonists Fig.”
Oh, H. S., Choi, M., Lee, T. S., An, Y., Park, E. J., Kim, T. H., Shin, S., & Shin, B. S. (2023) · Journal of Analytical Science & Technology · doi:10.1186/s40543-023-00382-5 · Cited by 20
“Brain distribution of liraglutide in rats It has been suggested that the benefits of liraglutide for weight loss and Alzheimer’s disease are associated with GLP-1 receptors in the brain (McClean et al. 2011; Farr et al. 2016; Adams et al. 2018; Lee and Kim 2020).”
BackgroundSucedaram, Y., Johns, E. J., Husain, R., Sattar, M. Z. A., Abdulla, M. H., Giribabu, N., Rahim, N. S., Khalilpourfarshbafi, M., & Abdullah, N. A. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s299083 · Cited by 19
ROSENKILDE, M. M., George, J. T., Véniant, M. M., & Holst, J. J. (2025) · Diabetes · doi:10.2337/dbi24-0027 · Cited by 19
Kamakura, R., Raza, G. S., Sodum, N., Lehto, V., Kovalainen, M., & Herzig, K. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200192 · Cited by 16
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Abcc5 Knockout Mice Have Lower Fat Mass and Increased Levels of Circulating GLP‐1
Cyranka, M., Veprik, A., McKay, E. J., van Loon, N., Thijsse, A., Cotter, L., Hare, N., Saibudeen, A., Lingam, S., Pires, E., et al. (2019) · Obesity · doi:10.1002/oby.22521 · Cited by 19
Le, T. D. V., Liu, D., Besing, G.-L. K., Raghavan, R., Ellis, B. J., Ceddia, R. P., Collins, S., & Ayala, J. E. (2023) · eLife · doi:10.7554/elife.80944 · Cited by 16
“This suggests that Raptor phosphorylation at Ser 791 by PKA contributes to the weight loss effect of GLP-1R agonists but not other G s-targeting pharmacological agents such as setmelanotide.”
BackgroundMonfort‐Pires, M., U-Din, M., Nogueira, G. A. S., de Almeida-Faria, J., Sidarta-Oliveira, D., Sant’Ana, M. R., Júnior, J. C. D. L., Cintra, D. E., de Souza, H. P., Ferreira, S. R. G., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa824 · Cited by 14
Lavoie, O., Turmel, A., Mattoon, P., Desrosiers, W. J., Plamondon, J., Michael, N. J., & Caron, A. (2024) · Neuroendocrinology · doi:10.1159/000538716 · Cited by 12
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Yacawych, W. T., Wang, Y., Zhou, G., Hassan, S., Bodur, Ç., Walters, E., Santinga, J. G., Sass, F., DeVaux, M., Kernodle, S., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci193743 · Cited by 19
Self-citationIncretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
“GLP-1R is expressed in feeding-related nuclei in the hypothalamus and brainstem (47, 48), and knockout from glutamatergic but not GABAergic neurons almost entirely abrogates GLP-1R agonist-induced weight loss in obese mice (49).”
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits
Hwang, E., Portillo, B., & Williams, K. W. (2025) · Endocrinology · doi:10.1210/endocr/bqaf125 · Cited by 10
Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetitePreprint
McMorrow, H. E., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.18.585583 · Cited by 10
“The GLP-1R is expressed in feeding-related nuclei in the hypothalamus and brainstem 42,43 , and knockout from glutamatergic but not GABAergic neurons almost entirely abrogates GLP-1R agonist-induced weight loss in obese mice 44 .”
BackgroundLiraglutide Impacts Iron Homeostasis in a Murine Model of Hereditary Hemochromatosis
Bozadjieva-Kramer, N., Shin, J. H., Blok, N. B., Jain, C., Das, N. K., Polex-Wolf, J., Knudsen, L. B., Shah, Y. M., & Seeley, R. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae090 · Cited by 12
Self-citationThe Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
Harej, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D., & Mršić‐Pelčić, J. (2024) · Pharmaceuticals · doi:10.3390/ph17101313 · Cited by 11
“Moreover, it is believed that GLP-1 receptors have key roles on glutamatergic, but not GABAergic, neurons [67].”
BackgroundNovel neural pathways targeted by GLP-1R agonists and bariatric surgery
Hankir, M. K., & Lutz, T. A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03047-3 · Cited by 16
“Notably, both systemic lira-glutide and semaglutide treatments robustly activate AP/ NTS, lPBN, and CeA neurons [51, 55] through GLP-1Rs expressed in glutamatergic, but not in GABAergic, neurons [55], possibly contributing to their aversive effects.”
Trapp, S., & Skoug, C. (2025) · Endocrinology · doi:10.1210/endocr/bqaf169 · Cited by 12
“Peripherally administered GLP-1RAs reduce food intake by engaging central nervous pathways (85-87), though most likely not via GLP1-Rs located inside the BBB (88).”
InfluentialShah, H., & Ayala, J. E. (2025) · Diabetes · doi:10.2337/db25-0678 · Cited by 16
In vivo transcriptomic, functional, circuit-based, and translational analyses of enteric neurons
Millett, C. J., Shaver, J. J., Bracken, B., Jones, S. J., Lovelett, R. J., Rubinow, D. A., Singhal, R., Charlton, C., Piazza, N., Hauck, Q., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.024 · Cited by 12
GLP‐1 at the Metabolic–Cognitive Interface: Reward, Affect, and Memory
Gao, S., Décarie-Spain, L., Gu, C., Mazzini, G., Kanoski, S. E., & Borner, T. (2026) · Comprehensive physiology · doi:10.1002/cph4.70129 · Cited by 14
Metadata
- Authors
- Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P.
- Affiliations
- University of Michigan (US)
- Harvard University (US)
- Corresponding author
- Olson, David P.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-05-18
- Volume
- 67
- Issue
- 8
- Pages
- 1538-1548
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054439
- OpenAlex
- W2803591279
- Cited by
- 159
- References
- 57
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 24 · 2023: 17 · 2022: 10 · 2021: 32 · 2020: 17 · 2019: 10 · 2018: 2
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (T32-DK-101357, DK-082480, DK-093848, DK-107652, DK-103703, DK-104999)
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, GLP-1 receptor, GLP-1 receptor agonists, glutamatergic neurons, GABAergic neurons, appetite regulation, dietary intake, weight loss, neural network activation, VGLUT2, vesicular GABA transporter
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Appetite Depressants, Energy Intake, Hypoglycemic Agents, Hypothalamus, Male, Mice, Transgenic, Nerve Net, Nerve Tissue Proteins, Neurons, Obesity, Random Allocation, Recombinant Fusion Proteins, Weight Loss, Genes, Reporter, Mice, Knockout, Green Fluorescent Proteins, Vesicular Inhibitory Amino Acid Transport Proteins, Vesicular Glutamate Transport Protein 2, Diet, High-Fat, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.